Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
M	O
Service:	O
MEDICINE	O
Allergies:	O
Latex	O
/	O
Theophylline	O
Attending:	O
___.	O
Chief	O
Complaint:	O
Dilated	O
intrahepatic/CBD	O
on	O
imaging,	O
weight	B-Weight_loss
loss,	B-Weight_loss
dark	O
urine	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
MRCP	O
___	O
Magnetic	O
retrograde	O
cholangiopancreatogram	O
ERCP	O
___	O
Endoscopic	O
retrograde	O
cholangiopancreatogram	O
History	O
of	O
Present	O
Illness:	O
___	O
with	O
decreased	O
appetite	O
and	O
anorexia	B-Malnutrition
x	O
months.	O
Had	O
dark	O
urine	O
a	O
few	O
weeks	O
prior	O
to	O
admission,	O
which	O
turned	O
bloody;	O
saw	O
urologist,	O
who	O
performed	O
cystoscopy,	O
and	O
had	O
a	O
foley	O
placed.	O
The	O
blood	O
in	O
the	O
foley	O
catheter	O
turned	O
bloody,	O
so	O
he	O
brought	O
by	O
his	O
wife	O
to	O
the	O
___.	O
A	O
CT	O
scan	O
was	O
done	O
on	O
___,	O
and	O
the	O
report	O
sent	O
to	O
his	O
primary	O
care	O
doctor	O
___	O
"distended	O
gall	O
bladder",	O
+	O
gall	O
stones,	O
+	O
dilation	O
of	O
intrahepatic	O
bile	O
duct	O
and	O
CBD	O
without	O
definite	O
CBD	O
stone,	O
and	O
2	O
large	O
stones	O
in	O
the	O
left	O
renal	O
pelvis).	O
Then	O
directly	O
admitted	O
by	O
PCP	O
for	O
evaluation	O
of	O
intrahepatic	O
bile	O
duct/CBD	O
dilation	O
(via	O
ERCP)	O
and	O
possible	O
cholecystectomy.	O
Past	O
Medical	O
History:	O
-dilated	O
cardiomyopathy,	O
CHF	O
with	O
EF	O
35%	O
-PAF	O
s/p	O
DC	O
cardioversion	O
___,	O
tx	O
Coumadin	O
-asthma/COPD	O
-GERD,	O
H.Pylori	O
gastritis	O
-SNHL	O
-radical	O
prostatectomy	O
___	O
for	O
prostate	O
Ca	O
-nephrolithiasis	O
-spinal	O
stenosis	O
s/p	O
laminectomy	O
-rectal	O
prolapse,	O
s/p	O
hemorrhoidectomy	O
-macular	I-Visual_impairment
degeneration	B-Visual_impairment
-HTN	O
-hyperlipidemia	O
-rheumatoid	O
arthritis	O
-nephrolithiasis	O
Social	O
History:	O
___	O
Family	O
History:	O
He	O
reports	O
a	O
sister	O
who	O
is	O
deceased	O
who	O
had	O
some	O
form	O
of	O
heart	O
disease.	O
No	O
history	O
of	O
diabetes.	O
No	O
history	O
of	O
carcinomas.	O
Physical	O
Exam:	O
T98F,	O
BP	O
160/79,	O
HR	O
80,	O
RR	O
18,	O
Sat	O
98%RA	O
Elderly	O
man,	O
no	O
acute	O
distress	O
+	O
hearing	B-Hearing_impairment
aids	B-Hearing_impairment
No	O
scleral	O
icterus,	O
moist	O
mucus	O
membranes	O
RRR,	O
normal	O
S1/S2,	O
no	O
m/r/g	O
Lungs	O
CTA	O
bilaterally	O
Abdomen	O
soft,	O
no	O
hepatosplenomegaly,	O
non-tender,	O
non-distended	O
+	O
bowel	O
sounds	O
No	O
CVA	O
tenderness	O
A&O	B-Unspecified_cognitive_impairment
x	B-Unspecified_cognitive_impairment
1,	B-Unspecified_cognitive_impairment
per	O
wife	O
at	O
baseline	O
skin	O
warm,	O
well-perfused	O
Pertinent	O
Results:	O
___	O
04:29PM	O
URINE	O
MUCOUS-MANY	O
___	O
04:29PM	O
URINE	O
CA	O
OXAL-FEW	O
___	O
04:29PM	O
URINE	O
RBC-325*	O
WBC-6*	O
BACTERIA-FEW	O
YEAST-NONE	O
EPI-0	O
___	O
04:29PM	O
URINE	O
BLOOD-LG	O
NITRITE-NEG	O
PROTEIN-30	O
GLUCOSE-NEG	O
KETONE-NEG	O
BILIRUBIN-NEG	O
UROBILNGN-NEG	O
PH-6.5	O
LEUK-SM	O
___	O
04:29PM	O
URINE	O
COLOR-Yellow	O
APPEAR-Hazy	O
SP	O
___	O
___	O
05:05PM	O
___	O
PTT-36.8*	O
___	O
___	O
05:05PM	O
PLT	O
COUNT-217	O
___	O
05:05PM	O
NEUTS-67.9	O
___	O
MONOS-7.6	O
EOS-3.0	O
BASOS-0	O
___	O
05:05PM	O
WBC-5.2	O
RBC-4.48*	O
HGB-11.4*	O
HCT-36.1*	O
MCV-81*	O
MCH-25.5*#	O
MCHC-31.7	O
RDW-16.8*	O
___	O
05:05PM	O
CALCIUM-8.6	O
PHOSPHATE-3.4	O
MAGNESIUM-2.1	O
___	O
05:05PM	O
LIPASE-39	O
GGT-1591*	O
___	O
05:05PM	O
ALT(SGPT)-105*	O
AST(SGOT)-123*	O
LD(LDH)-132	O
ALK	O
PHOS-1318*	O
TOT	O
BILI-1.1	O
___	O
05:05PM	O
estGFR-Using	O
this	O
___	O
05:05PM	O
GLUCOSE-97	O
UREA	O
N-15	O
CREAT-0.5	O
SODIUM-141	O
POTASSIUM-4.0	O
CHLORIDE-105	O
TOTAL	O
CO2-30	O
ANION	O
GAP-10	O
ECG	O
___:	O
Sinus	O
rhythm	O
with	O
ventricular	O
premature	O
beats	O
and	O
first	O
degree	O
A-V	O
block.	O
Non-specific	O
intraventricular	O
conduction	O
delay	O
of	O
the	O
left	O
bundle-branch	O
block	O
type.	O
Cannot	O
exclude	O
an	O
inferior	O
myocardial	O
infarction.	O
Poor	O
R	O
wave	O
progression	O
could	O
be	O
due	O
to	O
intraventricular	O
conduction	O
delay	O
but	O
cannot	O
exclude	O
an	O
anterior	O
myocardial	O
infarction.	O
Possible	O
left	O
ventricular	O
hypertrophy.	O
Non-specific	O
ST-T	O
wave	O
changes.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
___	O
ventricular	O
premature	O
beat	O
is	O
new.	O
There	O
is	O
loss	O
of	O
R	O
wave	O
in	O
leads	O
V4-V6	O
which	O
could	O
be	O
due	O
to	O
lead	O
placement.	O
MRCP	O
___:	O
Cholelithiasis	O
and	O
choledocholithiasis,	O
with	O
relatively	O
smooth	O
tapering	O
of	O
distal	O
CBD	O
in	O
its	O
superior	O
intrapancreatic	O
portion.	O
No	O
current	O
evidence	O
of	O
obstructing	O
choledocholithiasis.	O
While	O
the	O
appearance	O
is	O
more	O
suggestive	O
of	O
a	O
benign	O
stricture	O
from	O
passed	O
stones	O
or	O
sequelae	O
of	O
prior	O
pancreatitis	O
(though	O
there	O
is	O
no	O
evidence	O
of	O
acute	O
or	O
chronic	O
pancreatitis),	O
a	O
cholangiocarcinoma	O
remains	O
a	O
consideration	O
that	O
must	O
be	O
excluded.	O
Recommend	O
ERCP	O
for	O
decompression,	O
stone	O
removal,	O
and	O
obtaining	O
brush	O
sampling.	O
Markedly	O
distended	O
gallbladder	O
with	O
gallbladder	O
wall	O
irregularity	O
and	O
one	O
area	O
concerning	O
for	O
evolving	O
ischemic	O
gallbladder	O
wall.	O
ERCP:	O
___	O
Major	O
Papilla:	O
Normal	O
major	O
papilla	O
Cannulation:	O
Cannulation	O
of	O
the	O
biliary	O
duct	O
was	O
successful	O
and	O
deep	O
with	O
a	O
sphincterotome	O
after	O
a	O
guidewire	O
was	O
placed.	O
Contrast	O
medium	O
was	O
injected	O
resulting	O
in	O
complete	O
opacification.	O
Biliary	O
Tree:	O
A	O
single	O
stricture	O
that	O
was	O
2	O
cm	O
long	O
was	O
seen	O
at	O
the	O
middle	O
third	O
of	O
the	O
common	O
bile	O
duct.	O
There	O
was	O
moderate	O
post-obstructive	O
dilation.	O
A	O
sphincterotomy	O
was	O
performed	O
in	O
the	O
12	O
o'clock	O
position	O
using	O
a	O
sphincterotome	O
over	O
an	O
existing	O
guidewire.	O
Cytology	O
samples	O
were	O
obtained	O
for	O
histology	O
using	O
a	O
brush	O
from	O
the	O
CBD	O
stricture.	O
A	O
7cm	O
by	O
___	O
Cotton	O
___	O
biliary	O
stent	O
was	O
placed	O
successfully.	O
Impression:	O
Normal	O
major	O
papilla	O
A	O
single	O
stricture	O
that	O
was	O
2	O
cm	O
long	O
was	O
seen	O
at	O
the	O
middle	O
third	O
of	O
the	O
common	O
bile	O
duct.	O
There	O
was	O
moderate	O
post-obstructive	O
dilation.	O
A	O
sphincterotomy	O
was	O
performed	O
in	O
the	O
12	O
o'clock	O
position	O
using	O
a	O
sphincterotome	O
over	O
an	O
existing	O
guidewire.	O
Cytology	O
samples	O
were	O
obtained	O
for	O
histology	O
using	O
a	O
brush	O
from	O
the	O
CBD	O
stricture.	O
A	O
7cm	O
by	O
___	O
Cotton	O
___	O
biliary	O
stent	O
was	O
placed	O
successfully	O
Otherwise	O
normal	O
ercp	O
to	O
third	O
part	O
of	O
the	O
duodenum	O
Brief	O
Hospital	O
Course:	O
___	O
with	O
multiple	O
medical	O
problems	O
directly	O
admitted	O
from	O
___'s	O
office	O
for	O
evaluation	O
of	O
intermittent	O
dark	O
urine	O
and	O
dyspepsia,	O
for	O
evaluation	O
by	O
ERCP.	O
Intrahepatic	O
ductal/CBD	O
dilation:	O
Seen	O
by	O
ERCP	O
on	O
___,	O
recommended	O
MRCP	O
on	O
___,	O
reversal	O
of	O
INR,	O
and	O
ERCP	O
(potentially	O
on	O
___	O
for	O
evaluation	O
of	O
bile	O
duct	O
dilatation.	O
Had	O
MRCP	O
on	O
___,	O
demonstrating	O
cholelithiasis	O
and	O
choledocholithiasis,	O
with	O
markedly	O
distended	O
CBD	O
and	O
gallbladder.	O
GB	O
wall	O
irregular,	O
may	O
be	O
ischemic,	O
with	O
a	O
sharp	O
tapering	O
of	O
the	O
CBD	O
just	O
proximal	O
to	O
the	O
pancreatic	O
duct.	O
Seen	O
by	O
surgery,	O
who	O
recommended	O
ERCP	O
with	O
brushings	O
to	O
evaluate	O
smooth	O
tapering	O
(?malignancy).	O
s/p	O
ERCP	O
on	O
___,	O
with	O
sphincterotomy	O
and	O
stent	O
placement,	O
brushings	O
demonstrated	O
adeno	O
carcinoma.	O
No	O
anticoagulation	O
x	O
72	O
hours	O
after	O
procedure.	O
Will	O
need	O
replacement	O
of	O
plastic	O
stent	O
with	O
a	O
metal	O
stent	O
in	O
the	O
future	O
(currently	O
scheduled	O
for	O
___	O
with	O
Dr.	O
___.	O
Adenocarcinoma:	O
Etiology	O
unclear,	O
likely	O
cholangiocarcinoma	O
v	O
pancreatic	O
cancer.	O
Oncology	O
evaluated	O
patient	O
and	O
did	O
not	O
feel	O
he	O
was	O
a	O
candidate	O
for	O
chemotherapy	O
given	O
age	O
and	O
comorbidities.	O
Also	O
not	O
a	O
surgical	O
candidate,	O
discussed	O
with	O
surgery	O
attending,	O
in	O
addition,	O
patient	O
and	O
family	O
not	O
interested	O
in	O
surgery.	O
Palliative	O
Care	O
service	O
was	O
consulted	O
as	O
well.	O
Family	O
is	O
considering	O
hospice	O
care	O
as	O
an	O
outpatient,	O
have	O
been	O
given	O
a	O
list	O
of	O
potential	O
hospice	O
providers.	O
A	O
family	O
meeting	O
was	O
held	O
with	O
Dr.	O
___	O
care),	O
Dr.	O
___,	O
myself	O
(hospitalist/inpatient	O
attending),	O
social	O
work,	O
the	O
patients	O
wife	O
and	O
daughter	O
in	O
law.	O
At	O
this	O
time,	O
the	O
family	O
felt	O
strongly	O
about	O
not	O
telling	O
the	O
patient	O
about	O
his	O
diagnosis.	O
However,	O
they	O
want	O
to	O
tell	O
him	O
themselves	O
after	O
they	O
get	O
home.	B-Lives_alone
They	O
will	O
continue	O
to	O
discuss	O
this	O
with	O
Dr.	O
___	O
as	O
an	O
outpatient	O
and	O
all	O
the	O
medical	O
providers	O
present	O
at	O
the	O
meeting	O
offered	O
assistance	O
with	O
this.	O
In	O
general,	O
we	O
encouraged	O
them	O
to	O
disclose	O
this	O
information	O
to	O
him	O
and	O
it	O
was	O
decided	O
that	O
if	O
the	O
patient	O
inquires	O
about	O
his	O
diagnosis	O
while	O
he	O
is	O
here,	O
that	O
these	O
questions	O
will	O
be	O
answered.	O
Atrial	O
fibrillation	O
on	O
warfarin:	O
Received	O
2mg	O
PO	O
vitamin	O
K	O
x	O
3	O
for	O
INR	O
reversal	O
on	O
___	O
and	O
___.	O
Also	O
with	O
many	O
alarms	O
on	O
telemetry	O
for	O
"ventricular	O
tachycardia",	O
felt	O
by	O
EP	O
team	O
to	O
be	O
supraventricular	O
with	O
rate-related	O
aberrancy.	O
Amiodarone	O
(stopped	O
per	O
primary	O
cardiologist	O
in	O
the	O
setting	O
of	O
elevated	O
transaminases)	O
then	O
restarted.	O
Coumadin	O
restarted	O
on	O
___,	O
also	O
started	O
on	O
lovenox	O
given	O
high	O
___	O
score	O
and	O
newly	O
diagnosed	O
malignancy	O
for	O
bridging	O
until	O
therapeutic	O
on	O
coumadin.	O
goal	O
inr	O
___	O
Delirium:	B-Delirium
Noted	O
to	O
be	O
substantially	O
delirious	B-Delirium
overnight,	O
especially	O
in	O
the	O
early	O
morning,	O
refusing	O
medications,	O
thought	O
secondary	O
to	O
benzodiazepene	O
withdrawal,	O
sundowning,	O
and	O
acute	O
hospitalization	O
and	O
reversal	O
of	O
day/night.	O
Started	O
on	O
low-dose	O
seroquel	O
on	O
___	O
with	O
improvement.	O
Per	O
request	O
of	O
family	O
and	O
home	B-Lives_alone
care	O
giver,	O
ativan	O
changed	O
to	O
tid	O
and	O
quetiapine	O
to	O
___	O
dose.	O
Patient	O
tolerated	O
this	O
well	O
and	O
although	O
he	O
had	O
intermittent	O
episodes	O
of	O
confusion,	B-Delirium
his	O
mental	O
status	O
was	O
much	O
improved	O
by	O
the	O
time	O
of	O
discharge.	O
The	O
wife	O
was	O
concerned	O
about	O
sedation	O
with	O
seroquel,	O
I	O
explained	O
that	O
this	O
can	O
be	O
tapered	O
at	O
home	O
as	O
needed	O
(instructions	O
on	O
Rx),	O
but	O
that	O
he	O
was	O
tolerating	O
this	O
well	O
as	O
an	O
inpatient	O
Medications	O
on	O
Admission:	O
Keppra	O
500mg	O
BID	O
Ativan	O
0.25mg	O
Q4H	O
while	O
awake	O
Amiodarone	O
100mg	O
alternating	O
with	O
200mg	O
every	O
other	O
day	O
Sertraline	O
Warfarin	O
1mg	O
daily	O
Omeprazole	O
Advair	O
Mirtazapine	O
7.5mg	O
QHS	O
Simvastatin	O
Lisinopril	O
2.5mg	O
daily	O
Discharge	O
Medications:	O
1.	O
Enoxaparin	O
80	O
mg/0.8	O
mL	O
Syringe	O
Sig:	O
One	O
(1)	O
Subcutaneous	O
Q12H	O
(every	O
12	O
hours).	O
Disp:*28	O
*	O
Refills:*2*	O
2.	O
Fluticasone-Salmeterol	O
100-50	O
mcg/Dose	O
Disk	O
with	O
Device	O
Sig:	O
One	O
(1)	O
Disk	O
with	O
Device	O
Inhalation	O
BID	O
(2	O
times	O
a	O
day).	O
3.	O
Levetiracetam	O
500	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
BID	O
(2	O
times	O
a	O
day).	O
4.	O
Lisinopril	O
5	O
mg	O
Tablet	O
Sig:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
5.	O
Sertraline	O
50	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
6.	O
Simvastatin	O
10	O
mg	O
Tablet	O
Sig:	O
Two	O
(2)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
7.	O
Cyanocobalamin	O
500	O
mcg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
8.	O
Folic	O
Acid	O
1	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
9.	O
Omeprazole	O
20	O
mg	O
Capsule,	O
Delayed	O
Release(E.C.)	O
Sig:	O
One	O
(1)	O
Capsule,	O
Delayed	O
Release(E.C.)	O
PO	O
DAILY	O
(Daily).	O
10.	O
Pyridoxine	O
50	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
11.	O
Amiodarone	O
200	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
4X/WEEK	O
(___).	O
12.	O
Amiodarone	O
200	O
mg	O
Tablet	O
Sig:	O
0.5	O
Tablet	O
PO	O
3X/WEEK	O
(___).	O
13.	O
Quetiapine	O
25	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
HS	O
(at	O
bedtime):	O
can	O
decrease	O
to	O
___	O
tablet	O
at	O
night	O
if	O
getting	O
too	O
drowsy,	O
can	O
stop	O
after	O
a	O
week	O
at	O
___	O
tab	O
if	O
still	O
too	O
drowsy.	O
Disp:*30	O
Tablet(s)*	O
Refills:*2*	O
14.	O
Mirtazapine	O
15	O
mg	O
Tablet	O
Sig:	O
0.25	O
Tablet	O
PO	O
HS	O
(at	O
bedtime).	O
15.	O
Lorazepam	O
0.5	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
TID	O
(3	O
times	O
a	O
day)	O
as	O
needed	O
for	O
anxiety.	O
16.	O
Warfarin	O
1	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
QHS	O
(once	O
a	O
day	O
(at	O
bedtime)).	O
Discharge	O
Disposition:	O
Home	B-Lives_alone
With	O
Service	B-Has_carers
Facility:	O
___	O
Discharge	O
Diagnosis:	O
Newly	O
diagnosed	O
adeno	O
carcinoma	O
on	O
bile	O
duct	O
brushings	O
Discharge	O
Condition:	O
Somewhat	O
confused	B-Delirium
at	O
times.	O
Has	O
24	O
hour	O
care	O
at	O
home;	O
Clinically	O
stable.	O
Discharge	O
Instructions:	O
You	O
were	O
admitted	O
with	O
obstruction	O
of	O
your	O
gall	O
bladder	O
duct.	O
You	O
underwent	O
a	O
procedure	O
called	O
ERCP	O
where	O
this	O
obstruction	O
was	O
stented.	O
Brushings	O
from	O
this	O
were	O
done	O
came	O
back	O
with	O
malignant	O
(cancer)	O
cells.	O
This	O
could	O
be	O
originating	O
from	O
your	O
gall	O
bladder	O
or	O
pancreas.	O
Followup	O
Instructions:	O
___	O

